Arturo Mangas

Dr. Arturo Mangas


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Neuroscience
Verified
Journal Article
Closed access
AMArturo Mangas
Arturo Mangas
Rafael Coveñas RodríguezRafael Coveñas Rodríguez
Rafael Coveñas Rodríguez
DBD. Bodet
D. Bodet
MGM. Geffard
M. Geffard
LAL.A. Aguilar
L.A. Aguilar
JYJ. Yajeya
J. Yajeya

23 February 2014 in Journal of Amino Acids
Verified
Journal Article
Open access
PDF file
LVLaetitia Vidal
Laetitia Vidal
VTVéronique Thuault
Véronique Thuault
AMArturo Mangas
Arturo Mangas
Rafael Coveñas RodríguezRafael Coveñas Rodríguez
Rafael Coveñas Rodríguez
ATAnne Thienpont
Anne Thienpont
MGMichel Geffard
Michel Geffard
The development of multiple antibiotic resistance is a global problem. It is necessary to find new tools whose mechanisms of action differ from those of currently used antibiotics. It is known that fatty acids and cationic polypeptides are able to fight bacteria. Here, we describe the synthesis of fatty acids linked to a polypeptide with antibacterial activity. The linkage of fatty acids to a polypeptide is reported to increase the antibacterial effect of the linked fatty acid in comparison with free fatty acids (FA) or free poly-L-lysine (PLL) or a mixture of both (FA free + PLL free). A number of C6–C18fatty acids were linked to PLL to obtain new synthetic products. These compounds were assessedin vitroto evaluate their antibacterial activity. Some fatty acid-PLLs showed a good ability to fight bacteria. Their bactericidal activity was evaluated, and, lauryl linked to PLL was found to be the most active product against both Gram-positive and Gram-negative bacteria. This new active component showed a good degree of specificity and reproducibility and its minimum inhibitory concentration (MIC) was comparatively good. The antibacterial activity of the lauryl-PLL compound suggests that it is a new and promising antimicrobial agent.

31 July 2008 in Journal of Chemical Neuroanatomy
Verified
Journal Article
Closed access
ESEliana de Souza
Eliana de Souza
Rafael Coveñas RodríguezRafael Coveñas Rodríguez
Rafael Coveñas Rodríguez
PYPedro Yi
Pedro Yi
LALuís Angel Aguilar
Luís Angel Aguilar
LLLuís Lerma
Luís Lerma
JNJosé Angel Narváez
José Angel Narváez

1 January 2010 in International Journal of Alzheimer's Disease
Verified
Journal Article
Open access
PDF file
SDS. Duleu
S. Duleu
AMArturo Mangas
Arturo Mangas
FSF. Sevin
F. Sevin
BVB. Veyret
B. Veyret
ABA. Bessede
A. Bessede
MGM. Geffard
M. Geffard
In Alzheimer's disease, indoleamine 2,3-dioxygenase and tryptophan hydroxylase are known to induce an overproduction of neurotoxic compounds, such as quinolinic acid and 3-hydroxykynurenine from the former, and 5-hydroxytryptophol and 5-methoxytryptophol from the latter. Other compounds, such as kynurenic acid, serotonin, and melatonin are produced via the same pathways. An improved ELISA method identified circulating antibodies directed against these compounds, linked to proteins, as previously described for other chronic diseases. This describes how only the A isotype of circulating immunoglobulins recognized a pattern of conjugated tryptophan metabolites in the sera of Alzheimer patients. These data indirectly confirmed the involvement of tryptophan derivatives in the pathogenic processes of Alzheimer's disease. Further studies are required to evaluate the relevance of these antibody patterns in monitoring this disease.

1 June 2010 in Current Opinion in Neurology
Verified
Journal Article
Closed access
AMArturo Mangas
Arturo Mangas
Rafael Coveñas RodríguezRafael Coveñas Rodríguez
Rafael Coveñas Rodríguez
MGMichel Geffard
Michel Geffard
Multiple sclerosis (MS) is an autoimmune and inflammatory disease of the central nervous system (CNS) that causes neurological disability in young adults and that to date has no cure. Until now, expensive and only partially efficacious therapies have become available. For this reason, researchers, clinicians and pharmaceutical companies are currently investigating new drugs for the treatment of MS. Here, we review the most recent data on drug candidates for MS. In the preclinical phase, such drug candidates have shown a beneficial effect on the onset of experimental autoimmune encephalomyelitis (microtubule-stabilizing drugs, MS14, Lithium, GEMSP...), a decrease in CNS cell infiltrates (recombinant T cell receptor ligand, lovastatin-rolipram, ribavirin, GEMSP...), prevention of demyelination (lovastatin-rolipram, calpain inhibitor, lithium...); and a reduction of axonal loss (phenytoin, lovastatin-rolipram, calpain inhibitor). In clinical trials, drug candidates against MS have shown safety (rituximab, ustekinumab, intravenous immunoglobulin, laquinimod, BHT-3009, fumarate, chaperonin 10, GEMSP...), an improvement of gadolinium-enhanced lesions (protiramer, fingolimod, laquinimod, BHT-3009, fumarate, daclizumab...), and an improvement of the relapse rate (fingolimod, fumarate...). Future research into MS should focus on a combination of therapies and on the development of drugs directed against the remitting and progressive phases of the disease. In this sense, MS is a very complex multifactorial disease that requires treatment able to cover all the aspects of MS and not only the anti-inflammatory aspect.

25 October 2018 in European Journal of Histochemistry
Verified
Journal Article
Open access
PDF file
AMArturo Mangas
Arturo Mangas
MCMargarita Heredia Chons
Margarita Heredia Chons
ARAdelaida Riolobos
Adelaida Riolobos
AFAntonio De la Fuente
Antonio De la Fuente
JCJosé M. Criado
José M. Criado
Rafael Coveñas RodríguezRafael Coveñas Rodríguez
Rafael Coveñas Rodríguez
Using an immunohistochemical technique, we have studied the distribution of kynuneric acid (KYNA) and 3-hydroxyanthranilic acid (3-HAA) in a rat brain injury model (trauma). The study was carried out inducing a cerebral ablation of the frontal motor cortex. Two mouse monoclonal specific antibodies previously developed by our group directed against KYNA and 3-HAA were used. In control animals (sham-operated), the expression of both KYNA and 3-HAA was not observed. In animals in which the ablation was performed, the highest number of immunoreactive cells containing KYNA or 3-HAA was observed in the region surrounding the lesion and the number of these cells decreased moving away from the lesion. KYNA and 3-HAA were also observed in the white matter (ipsilateral side) located close to the injured region and in some cells placed in the white matter of the contralateral side. The distribution of KYNA and 3-HAA perfectly matched with the peripheral injured regions. The results found were identical independently of the perfusion date of animals (17, 30 or 54 days after brain injury). For the first time, the presence of KYNA and 3-HAA has been described in a rat trauma model. Moreover, by using a double immunocytochemistry protocol, it has been demonstrated that both metabolites were located in astrocytes. The findings observed suggest that, in cerebral trauma, KYNA and 3-HAA are involved in tissue damage and that these compounds could act, respectively, as a neuroprotector and a neurotoxic. This means that, in trauma, a counterbalance occurs and that a regulation of the indoleamine 2,3 dioxygenase (IDO) pathway could be required after a brain injury in order to decrease the deleterious effects of ending metabolites (the neurotoxic picolinic acid). Moreover, the localization of KYNA and 3-HAA in the contralateral side of the lesion suggests that the IDO pathway is also involved in the sprouting and pathfinding that follows a traumatic brain injury.